GLP1R and Hypoglycemia: On the contrary, lower proportions of discontinuers were observed among incident treatments of more recently marketed ADs, such as GLP1-RA, DPP4 and metformin+DPP4i, which are generally well tolerated, and are associated with weight loss and low risk of hypoglycemia [36].